Tinlarebant (LBS-008)

Name: Tinlarebant (LBS-008) in Stargardt disease type 1: Pathophysiology
Published: 2026-09-14T15:39:06-04:00

Stargardt disease type 1

Manufacturer: Belite Bio
Regulatory submission: NDA submitted June 2026
Launch: Anticipated in March 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description

Pathophysiology

1 evidence topic · 2 sources

Bisretinoids and early photoreceptor pathology: review

“Bisretinoids as a Source of Early Photoreceptor Pathology in Stargardt Disease” (opens the source at this quote in a new tab)
“formation and accumulation of bisretinoids begin within photoreceptors” (opens the source at this quote in a new tab)